Celcuity is a cellular analysis company that is discovering new cancer sub-types and commercializing diagnostic tests designed to significantly improve the clinical outcomes of cancer patients treated with targeted therapies. We: identify the signaling dysfunction driving a patientâs cancer that genetic tests cannot detect; directly measure the effectiveness of a targeted therapy in patientâs living tumor cells; confirm the therapeutic matching the patientâs cancer driver is present and functional in the cells before prescribing treatment, striving to improve the likelihood of a positive clinical outcome. Source
No articles found.
The discovery of immunosuppressive (anti-rejection) drugs has made possible life-s...
The discovery of immunosuppressive (anti-reject...
Pulmatrix is a clinical stage biopharmaceutical company developing innovative inha...
Pulmatrix is a clinical stage biopharmaceutical...
Founded in 1998, GW is a biopharmaceutical company focused on discovering, develop...
Founded in 1998, GW is a biopharmaceutical comp...
At Delee were fundamentally changing not only the way cancer is detected but also...
At Delee were fundamentally changing not only ...
H&G Science aims to facilitate the safe and effective treatment of diseases. Our g...
H&G Science aims to facilitate the safe and eff...
LuminexÂŽ Corporation (NASDAQ: LMNX) develops, manufactures and markets proprietar...
LuminexÂŽ Corporation (NASDAQ: LMNX) develops, ...
OPKO Health, Inc. is a diversified healthcare company that seeks to serve unmet pa...
OPKO Health, Inc. is a diversified healthcare c...
T2 Biosystems, a leader in the development and commercialization of innovative med...
T2 Biosystems, a leader in the development and ...
Semler Scientific, Inc. is an emerging medical risk-assessment company whose diagn...
Semler Scientific, Inc. is an emerging medical ...
Allogene Therapeutics is a clinical stage biotechnology company pioneering the dev...
Allogene Therapeutics is a clinical stage biote...
Join the National Investor Network and get the latest information with your interests in mind.